Pioneering the implementation of a precision oncology strategy in Portugal: the Precision Oncology Platform trial
DOI:
https://doi.org/10.2340/1651-226X.2023.33322Keywords:
Precision Oncology, targeted treatment, DRUP-like Clinical Trials (DLCTs), Precision Oncology Platform (POP) trialAbstract
Background and purpose: The Precision Oncology Platform (POP) trial represents the effort of the Portuguese Oncology Institute of Porto (IPO Porto) for joining other leading European institutions in both ‘Personalised Cancer Medicine for all EU citizens’ (PCM4EU), and ‘PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials’ (PRIME-ROSE) consortia, enabling the development of the Portuguese version of the Drug Rediscovery Protocol (DRUP)-like Clinical Trial (DLCT), based on the experience of the DRUP trial developed in The Netherlands.
Patients/material and methods: The POP trial is a phase II, pragmatic multicentric, non-randomised, open-label study, designed entirely like the other DLCTs. Its primary objective is to describe anti-tumour activity of targeted anticancer drugs in patients with advanced malignancies harbouring actionable molecular alterations. The primary endpoint is disease control rate (DCR). Secondary endpoints encompass treatment-related grade ≥3 adverse events, objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Exploratory objectives will assess biomarkers, resource use and costs, and patient-reported outcome measures (PROMs).
Interpretation: The POP trial will offer access to innovative treatments for patients without further therapeutic options and provide evidence on efficacy and safety of molecularly-guided treatments. Methodologically, it represents a pioneer approach in Portugal, including a pay-for-performance model embedded in the clinical trial. The POP trial represents a unique opportunity to integrate clinical research within cancer care, pursuing an evidence-based precision oncology strategy, and facilitating its rational and cost-effective implementation into the Portuguese healthcare system.
Downloads
References
PCM4EU [Internet]. [cited 04-10-2023]. Available from: https://health.ec.europa.eu/non-communicable-diseases/cancer/europes-beating-cancer-plan-eu4health-financed-projects/projects/pcm4eu_en
Home [Internet]. [cited 04-10-2023]. Available from: https://www.matrix-fkb.no/en/prime-rose/home
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491–1505.
https://doi.org/10.1016/j.annonc.2020.07.014 DOI: https://doi.org/10.1016/j.annonc.2020.07.014
van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P et al. The drug rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019;574(7776):127–131.
https://doi.org/10.1038/s41586-019-1600-x DOI: https://doi.org/10.1038/s41586-019-1600-x
Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, et al. Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. J Transl Med. 2022;20(1):225. DOI: https://doi.org/10.1186/s12967-022-03432-5
Kringelbach T, Højgaard M, Rohrberg K, Spanggaard I, Laursen BE, Ladekarl M, et al. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial. BMC Cancer. 2023;23(1):182.
https://doi.org/10.1186/s12885-023-10632-9 DOI: https://doi.org/10.1186/s12885-023-10632-9
https://apifarma.pt/ [Internet]. [cited 28-11-2023]. Equipa – Apifarma. Available from: https://apifarma.pt/quem-somos/organizacao-interna/equipa/
Jung SH. Admissible two-stage designs for phase II cancer clinical trials. Stat Med. 2004;23(4):561–569.
https://doi.org/10.1002/sim.1600 DOI: https://doi.org/10.1002/sim.1600
Simon R. Optimal two-stage designs for phase II clinical trials. Contr Clin Trials. 1989;10(1):1–10.
https://doi.org/10.1016/0197-2456(89)90015-9 DOI: https://doi.org/10.1016/0197-2456(89)90015-9
Mazzucco W, Pastorino R, Lagerberg T, Colotto M, D’Andrea E, Marotta C et al. Current state of genomic policies in healthcare among EU member states: results of a survey of chief medical officers. Eur J Public Health. 2017;27(5):931–937.
https://doi.org/10.1093/eurpub/ckw155 DOI: https://doi.org/10.1093/eurpub/ckw155
EFPIA. Unlocking the potential of precision medicine in Europe. Improving cancer care through broader access to quality biomarker testing. 2021.
Beccia F, Hoxhaj I, Castagna C, Strohäker T, Cadeddu C, Ricciardi W et al. An overview of personalized medicine landscape and policies in the European Union. Eur J Public Health. 2022;32(6):844–851.
https://doi.org/10.1093/eurpub/ckac103 DOI: https://doi.org/10.1093/eurpub/ckac103
Stenzinger A, Moltzen EK, Winkler E, Molnar-Gabor F, Malek N, Costescu A et al. Implementation of precision medicine in healthcare – a European perspective. J Intern Med. 2023;294(4):437–454.
https://doi.org/10.1111/joim.13698 DOI: https://doi.org/10.1111/joim.13698
Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, Enerly E et al. A national precision cancer medicine implementation initiative for Norway. Nat Med. 2022;28(5):885–887. DOI: https://doi.org/10.1038/s41591-022-01777-4
Caulfield M, Davies J, Dennys M, Elbahy L, Fowler T, Hill S et al. The 100,000 Genomes Project Protocol. Genom England Protocol. 2017;January:1–112.
Lejeune C, Amado IF. Valuing genetic and genomic testing in France: current challenges and latest evidence. J Community Genet. 2022;13(5):477–485.
https://doi.org/10.1007/s12687-020-00503-2 DOI: https://doi.org/10.1007/s12687-020-00503-2
Valckenborgh E, Hébrant A, Antoniou A, Hoof W, Bussel J, Pauwels P. Roadbook for the implementation of next-generation sequencing in clinical practice in oncology and hemato-oncology in Belgium. Arch Public Health. 2018;76:1–7.
https://doi.org/10.1186/s13690-018-0295-z DOI: https://doi.org/10.1186/s13690-018-0295-z
Pitini E, Migliara G, Baccolini V, Isonne C, Mazzalai E, Turatto F et al. Managing the introduction of genomic applications into the National Health Service: a special challenge for health technology assessment in Italy. Front Public Health. 2022;10:932093.
https://doi.org/10.3389/fpubh.2022.932093 DOI: https://doi.org/10.3389/fpubh.2022.932093
Illert AL, Stenzinger A, Bitzer M, Horak P, Gaidzik VI, Möller Y et al. The German Network for Personalized Medicine to enhance patient care and translational research. Nat Med. 2023;29(6):1298–1301.
https://doi.org/10.1038/s41591-023-02354-z DOI: https://doi.org/10.1038/s41591-023-02354-z
APAH. Agenda Estratégica para o Futuro da Medicina de Precisão em Portugal. 2019.
EFPIA. Unlocking the potential of precision medicine in Europe. Improving cancer care through broader access to quality biomarker testing. Policy recommendations. 2021.
Cambrosio A, Campbell J, Keating P, Polk JB, Aguilar-Mahecha A, Basik M. Healthcare policy by other means: cancer clinical research as “oncopolicy”. Soc Sci Med. 2022;292:114576.
https://doi.org/10.1016/j.socscimed.2021.114576 DOI: https://doi.org/10.1016/j.socscimed.2021.114576
Faulkner E, Holtorf AP, Walton S, Liu CY, Lin H, Biltaj E et al. Being precise about precision medicine: what should value frameworks incorporate to address precision medicine? A report of the Personalized Precision Medicine Special Interest Group. Value Health. 2020;23(5):529–539.
https://doi.org/10.1016/j.jval.2019.11.010 DOI: https://doi.org/10.1016/j.jval.2019.11.010
Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E et al. Delivering precision oncology to patients with cancer. Nat Med. 2022;28(4):658–665. DOI: https://doi.org/10.1038/s41591-022-01717-2
https://doi.org/10.1038/s41591- 022-01717-2
Gonçalves FR, Santos S, Silva C, Sousa G. Risk-sharing agreements, present and future. ecancer. 2018;12:823.
https://doi.org/10.3332/ecancer.2018.823 DOI: https://doi.org/10.3332/ecancer.2018.823
Performance-based managed entry agreements for new medicines in OECD countries and EU member states: how they work and possible improvements going forward [Internet]. 2019 [cited 16-02-2023]. (OECD Health Working Papers; vol. 115). Report No.: 115. Available from: https://www.oecd-ilibrary.org/social-issues-migration-health/performance-based-managed-entry-agreements-for-new-medicines-in-oecd-countries-and-eu-member-states_6e5e4c0f-en
European Commission. Regulation (EU) 2021/2282 of the European Parliament and of The Council of 15 December 2021 on health technology assessment and amending Directive 2011/24/EU. 2021.
EUnetHTA. EUnetHTA Joint Action 3 – WP1: a future model of HTA cooperation. 2021, pp. 1–125.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Beatrice Mainoli, Joana Assis, José Dinis, Rui Henrique, Júlio Oliveira
This work is licensed under a Creative Commons Attribution 4.0 International License.
